Urodynamix Technologies is a Canadian medical device company focused non-invasive diagnostic products based on its proprietary near-infrared spectroscopy (NIRS) platform technology.
The Company is currently developing a portfolio of medical devices to aid in the diagnosis and treatment of urinary incontinence (UI), lower urinary tract symptoms (LUTS), benign prostatic
hyperplasia (enlarged prostate or BPH),
prostate cancer and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome.
Urodynamix Corporate Fact Sheet
Regulatory Filings on SEDAR
Presentations
From time to time the Company makes presentations to various interested groups. This presentation is revised on a monthly basis, and is available here for review. If you represent a group interested in attending a presentation, or you would like additional information regarding the Company, please do not hesitate to get in touch.
Urodynamix Presentation, Q3 2008 |
Registrars and Transfer Agents
For shareholder inquiries related to a change in share registration or address, lost share certificates, estate transfers, or to advise of duplicate mailings, please contact Urodynamix's transfer agent:
Computershare Trust Company of Canada
100 University Ave, 9th Floor
Toronto, ON M5J 2Y1
Tel: 1-800-564-6253
Email: service@computershare.com
Independent Auditors
Deloitte & Touche LLP
1055 Dunsmuir Street
Vancouver, BC V7X 1P4
Contact Urodynamix
Jonathan Jackson, CA
Chief Financial Officer
Phone: (604) 638-0248
Fax: (604) 694-7771
Email: jjacksonn@urodynamix.com
Forward-Looking Statements
Certain statements contained in documents on this website constitute “forward-looking statements”. When used in these documents, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “propose”, “anticipate”, “believe”, “forecast”, “estimate”, “expect” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the Company’s current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements.
Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not intend, and does not assume any obligation, to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments. |
